Chimeric virus-like particles produced by a non-natural particle- forming protein. The non-natural particle forming protein comprises a self-assembling particle-forming first amino acid sequence substantially homologous with a yeast retrotransposon Ty p1 protein and a second amino acid sequence. The ...
A phase I clinical trial recruiting in Canada evaluates the tolerability, immunogenicity and safety of a plant-derived recombinant coronavirus-like particle. The Medicago VLP vaccine was produced by plants as bioreactors to synthesize the S protein of SARS-CoV-2. Subsequently, these proteins assemble...
VIRUS-LIKE PARTICLE VECTOR AS A POLYVALENT PLATFORM FOR INTRACELLULAR DELIVERY OF HIGH-MOLECULAR-WEIGHT THERAPEUTIC SUBSTANCES, METHOD FOR GENERATING A VIRUS LIKE PARTICLE VECTOR AND USE OF A VIRUS-LIKE PARTICLE VECTOR AND A PHARMACEUTICAL COMPOSITION CONTAINING SAID VIRUS-LIKE PARTICLE VECTOR...
Chimeric papillomavirus (PV) virus-like particles (VLPs) based on the bovine papillomavirus type 1 (BPV-1) L1 protein were constructed by replacing the 23-carboxyl-terminal amino acids of the BPV1 major protein L1 with an artificial "polytope" minigene, containing known CTL epitopes of human PV...
Engineered virus-like particles (eVLPs) are promising vehicles for transient delivery of proteins and RNAs, including gene editing agents. We report a system for the laboratory evolution of eVLPs that enables the discovery of eVLP variants with improved
Chimeric hepatitis E virus-like particle as a carrier for oral-deliverydoi:10.1016/j.vaccine.2012.10.073Hepatitis E virusVirus like particleRecombinant capsid proteinHIV-1 epitopeTrypsin proteolysisQuaternary structureOral delivery with virus-like particles (VLPs) is advantageous because of the inherited ...
Virus-like particles (VLPs) are potentially promising delivery vehicles that in principle offer key benefits of both viral and nonviral delivery methods33. VLPs are formed by spontaneous assembly and budding of retroviral polyproteins that encapsulate cargo molecules from producer cells. VLPs lack a ...
The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for ...
Cases of VLP Production Creative Biolabs has made a long-term commitment to developing excellent-quality virus-like particle (VLP) products. Through years of study and expertise, our team has created various advanced systems for the manufacture, purification, and characterization of VLPs. With our ...
Messenger RNA vaccines lack specificity for dendritic cells (DCs)—the most effective cells at antigen presentation. Here we report the design and performance of a DC-targeting virus-like particle pseudotyped with an engineered Sindbis-virus glycoprotein that recognizes a surface protein on DCs, and ...